LONDON (Alliance News) - Life science company ValiRx PLC Thursday said it has filed a Phase IB/dose escalation study for its anti-cancer therapeutic, VAL201.
"This represents an ethical and Research & Development committee filing that is needed before approval to proceed in cancer cases is granted," the company said.
ValiRx said the trial on prostate cancer patients will be a first in-man study with real patients and will not require health volunteers.
A first in-man study is a clinical trial where a medical procedure, previously developed and assessed through in vitro or animal testing, or through mathematical modelling is tested on human subjects for the first time.
The clinical unit at University College London Hospital is being contracted to undertake the human work for this trial, it said.
The stock was trading at 0.449 pence Thursday, up 0.060 pence or 16.4%
By Anthony Tshibangu; anthonytshibangu@alliancenews.com; @AnthonyAllNews
Copyright 2013 Alliance News Limited. All Rights Reserved.
ValiRx (VAL)